Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy
Research Grant
Awarded By
Ocuphire Pharma, Inc.
Start Date
January 5, 2021
End Date
August 31, 2023
Awarded By
Ocuphire Pharma, Inc.
Start Date
January 5, 2021
End Date
August 31, 2023